is glp-1 safe to use Medications Infographic GLP-1 vs. GLP-1 + GIP:

Witschi A, Reddy S, Stofer B, Lauterburg BH

In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]

We hear you

Broad spectrum and full spectrum CBD products contain additional beneficial compounds, which may contribute to their overall effects.* The bottom line CBDs influence on sleep is an exciting area of research, and while it may improve overall sleep quality, there is no evidence to suggest it directly causes vivid dreams or nightmares

GLP-1 / GIP (DUAL AGONIST) Dual-agonist therapies that target both GLP-1 and GIP pathways may be evaluated by your provider when appropriate